Dr. Clay Siegall Extends his Efforts in the Field of Cancer Research

Clay Siegall Ph.D. is a powerful force in the field of cancer research. He co-founded Seattle Genetics in 1998 where he serves as the company’s CEO, president and the chairman of the board of directors. Seattle Genetics is a company dedicated to finding cures for cancers and in helping to ease the suffering of cancer patients. They have developed a group of antibody-based therapies that specifically attack cancer cells while leaving healthy cells unharmed. Their drug, ADCETRIS which was recently given accelerated approval by the U.S. Food and Drug Administration in 2011 shows incredible promise.
Siegall was appointed to the board of directors of Mirna Therapeutics, an Austin, Texas-based company founded in 2007 that like Siegall’s Seattle Genetics is focused on cancer research. Mirna Therapeutics has made advances in the realm of microRNA, an area of keen interest for Siegall. The combining of these two powerful companies researching and developing cures for cancer shows the altruistic goals of both Mirna Therapeutics and Siegall.
Siegall began his interest in oncology as a student at the University of Maryland studying Zoology. Siegall continued his education at George Washington University where he received his Ph.D. in Genetics. Before co-founding Seattle Genetics, he worked for the National Cancer Institute, the National Institute of Health, and the Bristol-Myers Squibb Pharmaceutical Research company. He has written extensively in his field of expertise, publishing 70 works along with obtaining 15 patents in his field of endeavor.
Mirna Therapeutics is fortunate to have Dr. Siegall on its board of directors, and the world is lucky to have a scientist and researcher like Dr. Siegall searching for cures to a terrible disease.